Herzig Shoshana J, Vaughn Byron P, Howell Michael D, Ngo Long H, Marcantonio Edward R
Division of General Medicine, Beth Israel Deaconess Medical Center, Brookline, MA 02446, USA.
Arch Intern Med. 2011 Jun 13;171(11):991-7. doi: 10.1001/archinternmed.2011.14. Epub 2011 Feb 14.
Acid-suppressive medications are increasingly prescribed for noncritically ill hospitalized patients, although the incidence of nosocomial gastrointestinal (GI) tract bleeding (GI bleeding) and magnitude of potential benefit from this practice are unknown. We aimed to define the incidence of nosocomial GI bleeding outside of the intensive care unit and examine the association between acid-suppressive medication use and this complication.
We conducted a pharmacoepidemiologic cohort study of patients admitted to an academic medical center from 2004 through 2007, at least 18 years of age, and hospitalized for 3 or more days. Admissions with a primary diagnosis of GI bleeding were excluded. Acid-suppressive medication use was defined as any order for a proton pump inhibitor or histamine-2-receptor antagonist. The main outcome measure was nosocomial GI bleeding. A propensity matched generalized estimating equation was used to control for confounders.
The final cohort included 78,394 admissions (median age, 56 years; 41% men). Acid-suppressive medication was ordered in 59% of admissions, and nosocomial GI bleeding occurred in 224 admissions (0.29%). After matching on the propensity score, the adjusted odds ratio for nosocomial GI bleeding in the group exposed to acid-suppressive medication relative to the unexposed group was 0.63 (95% confidence interval, 0.42-0.93). The number needed to treat to prevent 1 episode of nosocomial GI bleeding was 770.
Nosocomial GI bleeding outside of the intensive care unit was rare. Despite a protective effect of acid-suppressive medication, the number needed to treat to prevent 1 case of nosocomial GI bleeding was relatively high, supporting the recommendation against routine use of prophylactic acid-suppressive medication in noncritically ill hospitalized patients.
尽管医院获得性胃肠道(GI)出血的发生率以及这种做法的潜在获益程度尚不清楚,但非危重症住院患者使用抑酸药物的情况越来越普遍。我们旨在确定重症监护病房以外医院获得性GI出血的发生率,并研究使用抑酸药物与这种并发症之间的关联。
我们对2004年至2007年入住一所学术医疗中心、年龄至少18岁且住院3天或更长时间的患者进行了一项药物流行病学队列研究。排除以GI出血为主要诊断的入院患者。抑酸药物的使用定义为任何质子泵抑制剂或组胺-2受体拮抗剂的医嘱。主要结局指标是医院获得性GI出血。使用倾向匹配广义估计方程来控制混杂因素。
最终队列包括78394例入院患者(中位年龄56岁;41%为男性)。59%的入院患者使用了抑酸药物,224例入院患者(0.29%)发生了医院获得性GI出血。在倾向得分匹配后,使用抑酸药物组相对于未使用组发生医院获得性GI出血的调整后优势比为0.63(95%置信区间,0.42 - 0.93)。预防1例医院获得性GI出血所需治疗的患者数为770。
重症监护病房以外医院获得性GI出血很少见。尽管抑酸药物有保护作用,但预防1例医院获得性GI出血所需治疗的患者数相对较高,这支持了不建议在非危重症住院患者中常规使用预防性抑酸药物的观点。